BioAtla Inc (NASDAQ:BCAB) has a beta value of 1.15 and has seen 1.07 million shares traded in the recent trading session. The company, currently valued at $41.67M, closed the recent trade at $0.65 per share which meant it lost -$0.03 on the day or -4.07% during that session. The BCAB stock price is -518.46% off its 52-week high price of $4.02 and 12.31% above the 52-week low of $0.57. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.14 million shares traded. The 3-month trading volume is 1.10 million shares.
The consensus among analysts is that BioAtla Inc (BCAB) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.34.
BioAtla Inc (NASDAQ:BCAB) trade information
Sporting -4.07% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BCAB stock price touched $0.65 or saw a rise of 4.62%. Year-to-date, BioAtla Inc shares have moved 10.01%, while the 5-day performance has seen it change 1.94%. Over the past 30 days, the shares of BioAtla Inc (NASDAQ:BCAB) have changed -59.60%. Short interest in the company has seen 3.95 million shares shorted with days to cover at 4.65.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 87.0% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -669.23% off the targeted high while a plunge would see the stock gain -669.23% from the levels at last check today.
BioAtla Inc (BCAB) estimates and forecasts
Figures show that BioAtla Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -48.79% over the past 6 months, with this year growth rate of 43.41%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -25.30% over the past 5 years.
BCAB Dividends
BioAtla Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BioAtla Inc (NASDAQ:BCAB)’s Major holders
Insiders own 8.96% of the company shares, while shares held by institutions stand at 35.61% with a share float percentage of 39.12%. Investors are also buoyed by the number of investors in a company, with BioAtla Inc having a total of 80.0 institutions that hold shares in the company. The top two institutional holders are SOLEUS CAPITAL MANAGEMENT, L.P. with over 3.9 million shares worth more than $5.34 million. As of 2024-06-30, SOLEUS CAPITAL MANAGEMENT, L.P. held 8.113% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.89 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.58 million and represent 3.9205% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 2.63% shares in the company for having 1.27 shares of worth $0.82 million while later fund manager owns 549.45 shares of worth $0.36 million as of Sep 30, 2024, which makes it owner of about 1.14% of company’s outstanding stock.
